Vaxart (VXRT) Stock Forecast, Price Target & Predictions

OverviewRevenue Ownership Financials Chart Transcripts

VXRT Stock Forecast

Vaxart stock forecast is as follows: an average price target of $2.00 (represents a 222.79% upside from VXRT’s last price of $0.62) and a rating consensus of 'Hold', based on 3 wall street analysts offering a 1-year stock forecast.

VXRT Price Target

The average price target for Vaxart (VXRT) is $2.00 based on 1-year price targets from 3 Wall Street analysts in the past 3 months, with a price target range of $2.00 to $2.00. This represents a potential 222.79% upside from VXRT's last price of $0.62.

VXRT Analyst Ratings

Hold

According to 3 Wall Street analysts, Vaxart's rating consensus is 'Hold'. The analyst rating breakdown for VXRT stock is 0 'Strong Buy' (0.00%), 1 'Buy' (33.33%), 2 'Hold' (66.67%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Vaxart Price Target by Analyst

Date	Analyst	Company	Price Target	Price when Published	Price Target/Price when Published	Price Target/Last Closing Price
Jan 31, 2024	Mayank Mamtani	B.Riley Financial	$2.00	$1.18	69.49%	222.79%

The latest Vaxart stock forecast, released on Jan 31, 2024 by Mayank Mamtani from B.Riley Financial, set a price target of $2.00, which represents a 69.49% increase from the stock price at the time of the forecast ($1.18), and a 222.79% increase from VXRT last price ($0.62).

Vaxart Price Target by Period

	1M	3M	12M
# Anlaysts	-	-	1
Avg Price Target	-	-	$2.00
Last Closing Price	$0.62	$0.62	$0.62
Upside/Downside	-100.00%	-100.00%	222.79%

In the current month, the average price target of Vaxart stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Vaxart's last price of $0.62. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades

Date	Company	Previous Rating	New Rating	Rating Change
Aug 15, 2024	Oppenheimer	Outperform	Hold	Initialise
Aug 14, 2024	Oppenheimer		Outperform	Initialise
Dec 19, 2022	B. Riley Securities	Neutral	Neutral	Hold
Jun 12, 2021	Piper Sandler		Overweight	Initialise

Vaxart's last stock rating was published by Oppenheimer on Aug 15, 2024. The company Initialise its VXRT rating from "Outperform" to "Hold".

Vaxart Financial Forecast

Vaxart Revenue Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 17	Mar 16	Dec 15
Revenue	-	-	-	-	-	-	-	-	-	$446.00K	$1.36M	$675.00K	$22.00K	-	-	$85.00K	$74.00K	$200.00K	$112.00K	$506.00K	$356.00K	$265.00K	$523.00K	$2.90M	$3.92M	$454.00K	$85.00K	$4.90M	$5.30M	$1.70M
Avg Forecast	$16.49M	$15.54M	$14.14M	$12.39M	$20.78M	$1.93M	$100.00K	$800.00K	$833.33K	$100.00K	$83.33K	$800.00K	$675.00K	$50.00K	$96.75K	$125.00K	$182.75K	$118.40K	$549.25K	$617.00K	$4.35M	$1.07M	$1.27M	$2.80M	$600.00K	$443.00K	$1.10M	$9.55M	$6.81M	$1.10M
High Forecast	$30.40M	$28.65M	$26.07M	$19.10M	$37.53M	$3.55M	$184.41K	$1.48M	$1.48M	$184.41K	$153.67K	$1.48M	$1.24M	$50.00K	$96.75K	$125.00K	$182.75K	$118.40K	$549.25K	$617.00K	$4.35M	$1.07M	$1.27M	$2.80M	$600.00K	$443.00K	$1.10M	$11.45M	$8.18M	$1.32M
Low Forecast	$4.68M	$4.41M	$4.01M	$5.68M	$4.03M	$546.41K	$28.39K	$227.08K	$185.19K	$28.39K	$23.65K	$227.08K	$191.60K	$50.00K	$96.75K	$125.00K	$182.75K	$118.40K	$549.25K	$617.00K	$4.35M	$1.07M	$1.27M	$2.80M	$600.00K	$443.00K	$1.10M	$7.64M	$5.45M	$880.00K
# Analysts	1	1	1	2	3	1	1	1	2	1	1	1	1	1	1	1	1	1	1	1	1	1	7	9	8	6	10	14	8	9
Surprise %	-	-	-	-	-	-	-	-	-	4.46%	16.30%	0.84%	0.03%	-	-	0.68%	0.40%	1.69%	0.20%	0.82%	0.08%	0.25%	0.41%	1.04%	6.53%	1.02%	0.08%	0.51%	0.78%	1.55%

Vaxart's average Quarter revenue forecast for Dec 23 based on 2 analysts is $833.33K, with a low forecast of $185.19K, and a high forecast of $1.48M. VXRT's average Quarter revenue forecast represents a 86.85% increase compared to the company's last Quarter revenue of $446.00K (Sep 23).

Vaxart EBITDA Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 17	Mar 16	Dec 15
# Analysts	1	1	1	2	3	1	1	1	2	1	1	1	1	1	1	1	1	1	1	1	1	1	7	9	8	6	10	14	8	9
EBITDA	-	-	-	-	-	-	-	-	-	$-15.09M	$-22.53M	$-22.87M	$-17.44M	$-29.43M	$-27.87M	$-23.61M	$-19.20M	$-16.20M	$-14.76M	$-14.51M	$-12.49M	$-6.94M	$-7.89M	$-73.00K	$-4.93M	$-3.89M	$-4.01M	$-4.10M	$-5.20M	$-6.50M
Avg Forecast	$-16.49M	$-15.54M	$-14.14M	$-12.39M	$-20.78M	$-1.93M	$-100.00K	$-31.11M	$-833.33K	$-100.00K	$-83.33K	$-24.60M	$-24.29M	$-47.22K	$-91.37K	$-19.44M	$-172.59K	$-111.82K	$-518.71K	$-9.57M	$-4.11M	$-1.01M	$-1.20M	$-98.55K	$-566.63K	$-4.22M	$-1.04M	$-5.45M	$-6.36M	$-3.25M
High Forecast	$-4.68M	$-4.41M	$-4.01M	$-5.68M	$-4.03M	$-546.41K	$-28.39K	$-24.89M	$-185.19K	$-28.39K	$-23.65K	$-19.68M	$-19.44M	$-47.22K	$-91.37K	$-15.55M	$-172.59K	$-111.82K	$-518.71K	$-7.66M	$-4.11M	$-1.01M	$-1.20M	$-78.84K	$-566.63K	$-3.38M	$-1.04M	$-4.36M	$-5.08M	$-2.60M
Low Forecast	$-30.40M	$-28.65M	$-26.07M	$-19.10M	$-37.53M	$-3.55M	$-184.41K	$-37.34M	$-1.48M	$-184.41K	$-153.67K	$-29.52M	$-29.15M	$-47.22K	$-91.37K	$-23.33M	$-172.59K	$-111.82K	$-518.71K	$-11.49M	$-4.11M	$-1.01M	$-1.20M	$-118.26K	$-566.63K	$-5.07M	$-1.04M	$-6.54M	$-7.63M	$-3.90M
Surprise %	-	-	-	-	-	-	-	-	-	150.89%	270.37%	0.93%	0.72%	623.18%	305.02%	1.21%	111.28%	144.92%	28.45%	1.52%	3.04%	6.89%	6.60%	0.74%	8.70%	0.92%	3.86%	0.75%	0.82%	2.00%

undefined analysts predict VXRT's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Vaxart's previous annual EBITDA (undefined) of $NaN.

Vaxart Net Income Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 17	Mar 16	Dec 15
# Analysts	1	1	1	2	3	1	1	1	2	1	1	1	1	1	1	1	1	1	1	1	1	1	7	9	8	6	10	14	8	9
Net Income	-	-	-	-	-	-	-	-	-	$-17.40M	$-22.55M	$-25.14M	$-23.92M	$-29.31M	$-29.43M	$-25.10M	$-20.76M	$-17.58M	$-16.12M	$-16.01M	$-13.86M	$-8.09M	$-8.98M	$-1.30M	$-6.41M	$-5.26M	$-5.64M	$-4.40M	$-5.20M	$-6.50M
Avg Forecast	$-25.02M	$-20.47M	$-26.16M	$-28.43M	$-22.75M	$-22.86M	$-34.12M	$-33.08M	$-30.33M	$-40.94M	$-40.94M	$-26.15M	$-26.27M	$-44.79M	$-38.79M	$-20.67M	$-30.48M	$-26.60M	$-26.32M	$-10.56M	$-10.16M	$-17.24M	$-11.70M	$-1.75M	$-24.01M	$-5.71M	$-92.35M	$-5.85M	$-6.36M	$-3.25M
High Forecast	$-1.73M	$-1.41M	$-1.81M	$-19.68M	$-18.20M	$-1.58M	$-2.35M	$-26.46M	$-26.28M	$-2.83M	$-2.83M	$-20.92M	$-21.01M	$-44.79M	$-38.79M	$-16.54M	$-30.48M	$-26.60M	$-26.32M	$-8.45M	$-10.16M	$-17.24M	$-11.70M	$-1.40M	$-24.01M	$-4.57M	$-92.35M	$-4.68M	$-5.08M	$-2.60M
Low Forecast	$-52.47M	$-42.93M	$-54.86M	$-34.99M	$-25.02M	$-47.94M	$-71.55M	$-39.69M	$-32.35M	$-85.87M	$-85.87M	$-31.38M	$-31.52M	$-44.79M	$-38.79M	$-24.81M	$-30.48M	$-26.60M	$-26.32M	$-12.68M	$-10.16M	$-17.24M	$-11.70M	$-2.10M	$-24.01M	$-6.85M	$-92.35M	$-7.01M	$-7.63M	$-3.90M
Surprise %	-	-	-	-	-	-	-	-	-	0.42%	0.55%	0.96%	0.91%	0.65%	0.76%	1.21%	0.68%	0.66%	0.61%	1.52%	1.36%	0.47%	0.77%	0.74%	0.27%	0.92%	0.06%	0.75%	0.82%	2.00%

Vaxart's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. VXRT's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).

Vaxart SG&A Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 17	Mar 16	Dec 15
# Analysts	1	1	1	2	3	1	1	1	2	1	1	1	1	1	1	1	1	1	1	1	1	1	7	9	8	6	10	14	8	9
SG&A	-	-	-	-	-	-	-	-	-	$4.92M	$5.60M	$6.63M	$6.45M	$6.96M	$9.32M	$6.66M	$5.75M	$5.04M	$5.15M	$5.94M	$5.13M	$4.19M	$3.90M	$1.99M	$1.33M	$1.46M	$1.38M	$1.30M	$1.50M	$1.50M
Avg Forecast	$1.01B	$952.83M	$866.97M	$759.65M	$1.27B	$118.05M	$6.13M	$49.06M	$51.10M	$6.13M	$5.11M	$49.06M	$41.39M	$3.06M	$5.92M	$7.65M	$11.18M	$7.25M	$33.62M	$37.76M	$266.23M	$65.28M	$77.52M	$2.69M	$36.72M	$27.11M	$67.32M	$1.73M	$1.83M	$750.00K
High Forecast	$1.86B	$1.76B	$1.60B	$1.17B	$2.30B	$217.69M	$11.31M	$90.47M	$90.85M	$11.31M	$9.42M	$90.47M	$76.33M	$3.06M	$5.92M	$7.65M	$11.18M	$7.25M	$33.62M	$37.76M	$266.23M	$65.28M	$77.52M	$3.22M	$36.72M	$27.11M	$67.32M	$2.07M	$2.20M	$900.00K
Low Forecast	$287.00M	$270.46M	$246.09M	$348.25M	$246.92M	$33.51M	$1.74M	$13.93M	$11.36M	$1.74M	$1.45M	$13.93M	$11.75M	$3.06M	$5.92M	$7.65M	$11.18M	$7.25M	$33.62M	$37.76M	$266.23M	$65.28M	$77.52M	$2.15M	$36.72M	$27.11M	$67.32M	$1.38M	$1.47M	$600.00K
Surprise %	-	-	-	-	-	-	-	-	-	0.80%	1.10%	0.14%	0.16%	2.27%	1.57%	0.87%	0.51%	0.70%	0.15%	0.16%	0.02%	0.06%	0.05%	0.74%	0.04%	0.05%	0.02%	0.75%	0.82%	2.00%

Vaxart's average Quarter SG&A projection for Dec 23 is $51.10M, based on 2 Wall Street analysts, with a range of $11.36M to $90.85M. The forecast indicates a 938.48% rise compared to VXRT last annual SG&A of $4.92M (Sep 23).

Vaxart EPS Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 17	Mar 16	Dec 15
# Analysts	1	1	1	2	3	1	1	1	2	1	1	1	1	1	1	1	1	1	1	1	1	1	7	9	8	6	10	14	8	9
EPS	-	-	-	-	-	-	-	-	-	$-0.11	$-0.00	$-0.19	$-0.19	$-0.23	$-0.23	$-0.20	$-0.17	$-0.14	$-0.13	$-0.14	$-0.13	$-0.08	$-0.12	$-0.02	$-0.13	$-0.32	$-0.39	$-1.25	$-1.48	$-1.85
Avg Forecast	$-0.11	$-0.09	$-0.12	$-0.13	$-0.10	$-0.10	$-0.15	$-0.14	$-0.13	$-0.18	$-0.18	$-0.19	$-0.23	$-0.24	$-0.21	$-0.16	$-0.17	$-0.14	$-0.14	$-0.10	$-0.06	$-0.09	$-0.06	$-0.04	$-0.13	$-0.35	$-0.50	$-3.07	$-2.42	$-0.05
High Forecast	$-0.01	$-0.01	$-0.01	$-0.09	$-0.08	$-0.01	$-0.01	$-0.01	$-0.12	$-0.01	$-0.01	$-0.01	$-0.02	$-0.24	$-0.21	$-0.16	$-0.17	$-0.14	$-0.14	$-0.10	$-0.06	$-0.09	$-0.06	$-0.04	$-0.13	$-0.35	$-0.50	$-2.46	$-1.94	$-0.04
Low Forecast	$-0.23	$-0.19	$-0.24	$-0.15	$-0.11	$-0.21	$-0.31	$-0.29	$-0.14	$-0.38	$-0.38	$-0.39	$-0.48	$-0.24	$-0.21	$-0.16	$-0.17	$-0.14	$-0.14	$-0.10	$-0.06	$-0.09	$-0.06	$-0.04	$-0.13	$-0.35	$-0.50	$-3.68	$-2.90	$-0.07
Surprise %	-	-	-	-	-	-	-	-	-	0.61%	0.00%	1.02%	0.84%	0.95%	1.10%	1.23%	1.03%	0.97%	0.91%	1.40%	2.36%	0.86%	1.89%	0.50%	1.00%	0.90%	0.78%	0.41%	0.61%	37.00%

According to undefined Wall Street analysts, Vaxart's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to VXRT previous annual EPS of $NaN (undefined).

Vaxart Peer Comparison by Price Target

Ticker	Company	Last Closing Price	Avg Price Target	Upside/Downside	Avg Rating
CODX	Co-Diagnostics	$0.76	$6.00	689.47%
OCGN	Ocugen	$0.83	$5.00	502.41%	Buy
INO	Inovio Pharmaceuticals	$1.96	$8.00	308.16%	Buy
VXRT	Vaxart	$0.59	$2.00	238.98%	Hold
NVAX	Novavax	$9.00	$20.33	125.89%	Buy

VXRT Forecast FAQ

Is Vaxart a good buy?

No, according to 3 Wall Street analysts, Vaxart (VXRT) is considered a 'Hold'. The rating consensus is based on 0 'Strong Buy' and 1 'Buy' recommendations, accounting for 33.33% of VXRT's total ratings.

What is VXRT's price target?

Vaxart (VXRT) average price target is $2 with a range of $2 to $2, implying a 222.79% from its last price of $0.62. The data is based on 3 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Vaxart stock go up soon?

According to Wall Street analysts' prediction for VXRT stock, the company can go up by 222.79% (from the last price of $0.62 to the average price target of $2), up by 222.79% based on the highest stock price target, and up by 222.79% based on the lowest stock price target.

Can Vaxart stock reach $1?

VXRT's average twelve months analyst stock price target of $2 supports the claim that Vaxart can reach $1 in the near future.

What are Vaxart's analysts' financial forecasts?

Vaxart's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $23.6M (high $42.74M, low $4.83M), average EBITDA is $-53.918M (high $-29.493M, low $-78.603M), average net income is $-113M (high $-48.591M, low $-184M), average SG&A $1.45B (high $2.62B, low $296.1M), and average EPS is $-0.491 (high $-0.107, low $-0.929). VXRT's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $58.55M (high $104.22M, low $18.78M), average EBITDA is $-58.55M (high $-18.782M, low $-104M), average net income is $-100M (high $-24.628M, low $-185M), average SG&A $3.59B (high $6.39B, low $1.15B), and average EPS is $-0.44 (high $-0.108, low $-0.815).

Did the VXRT's actual financial results beat the analysts' financial forecasts?

Based on Vaxart's last annual report (Dec 2022), the company's revenue was $107K, which missed the average analysts forecast of $946.75K by -88.70%. Apple's EBITDA was $-106M, beating the average prediction of $-43.876M by 141.77%. The company's net income was $-108M, missing the average estimation of $-131M by -17.44%. Apple's SG&A was $29.39M, missing the average forecast of $58.03M by -49.36%. Lastly, the company's EPS was $-0.84, missing the average prediction of $-0.842 by -0.30%. In terms of the last quarterly report (Sep 2023), Vaxart's revenue was $446K, beating the average analysts' forecast of $100K by 346.00%. The company's EBITDA was $-15.089M, beating the average prediction of $-100K by 14989.00%. Vaxart's net income was $-17.4M, missing the average estimation of $-40.942M by -57.50%. The company's SG&A was $4.92M, missing the average forecast of $6.13M by -19.75%. Lastly, the company's EPS was $-0.11, missing the average prediction of $-0.18 by -38.89%